MET and non-small cell lung carcinoma: To confirm these achievements, a Chinese multicentre, open-label phase III trial is currently underway to assess the efficacy, safety and tolerability of savolitinib in NSCLC patients with MET exon 14 skipping mutations [NCT04923945].